FDA approves Sanofi’s all-oral treatment for sleeping sickness
Sanofi has developed the drug under the partnership with DNDi, and the National Sleeping Sickness Programmes of the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Jul 21
Sanofi has developed the drug under the partnership with DNDi, and the National Sleeping Sickness Programmes of the…
20 Jul 21
Drug distributors McKesson, Cardinal Health and AmerisourceBergen would jointly pay $21bn, while J&J alone would pay $5bn
19 Jul 21
Vaxneuvance triggered superior immune responses for serotypes 3, 22F and 33F compared to Merck’s 13-valent pneumococcal vaccine PCV13
19 Jul 21
The company aims to secure up to £400m in new private investment and create up to 5,000 new…
16 Jul 21
The new drug is currently being tested in a Phase 3 clinical trial in Kenya and Côte d’Ivoire
16 Jul 21
The company will expand its research and development capabilities in the Tarrytown campus
15 Jul 21
In a previous equity investment round, Lilly acquired a 14% stake in California-based Promoter
15 Jul 21
The collaboration will focus on the emergency use authorisation, promotion, and sale of proxalutamide for the treatment of…
14 Jul 21
The sale is part of Sanofi’s strategy to simplify its consumer healthcare portfolio and advance its growth
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Jul 21
WHO announced its decision to authorise Sinovac's CoronaVac for Emergency Use, following the review by SAGE